Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown

Fierce Biotech·Jun 11

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Takeda's TYK2 inhibitor has shown positive results in a phase 3 trial for psoriasis treatment, outperforming Bristol Myers' Sotyktu. The trial's success may pave the way for a potential FDA filing, with some reports suggesting a filing as early as 2026. The outcome of the trial has been seen as a significant development in the treatment of plaque psoriasis.

Full coverage

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

Yahoo Finance·Jun 11

Fierce Pharma Asia—Astellas CEO’s 5-year plan; Takeda’s psoriasis win; RA’s China bridge program

Fierce Pharma·Jun 12

Fierce Pharma Asia—Daiichi ADC's 1st-line nod, trial deaths; Takeda's TYK2 trial win

Fierce Pharma·Dec 19

Has Alumis's Envudeucitinib Redefined Psoriasis Treatment

Kavout | AI·Mar 28

Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success

Fierce Biotech·Dec 18

View original report at Fierce Biotech ↗

Fetching the latest headlines…